Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients

Study summary

The same initial and long-term anticoagulation is suggested for unsuspected pulmonary embolism as for patients with symptomatic embolism. Based on these indications, cancer patients with unsuspected pulmonary embolism would be anticoagulated for at least 6 months or until the disease is active, which in most cases would mean indefinite treatment. In fact, dedicated studies on the treatment of unsuspected pulmonary embolism are missing, leaving doubts over the need for (indefinite) anticoagulation which exposes these patients to an increased risk of major bleeding events. Concerns over the need for anticoagulant treatment may especially hold for pulmonary embolism of the distal pulmonary tree since segmental and sub-segmental PE seem to have a more benign course than more proximal embolism. The scope of this study is to evaluate the current treatment approaches for unsuspected pulmonary embolism and to assess their efficacy and safety in a large prospective cohort of cancer patients.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedHeparin, fondaparinux, vitamin-K antagonists, aspirin

The study team can explain what participation involves.

Who it may be forUnsuspected Pulmonary Embolism

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 8, 2019 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?46 U.S. locations

Locations may change over time.

Who runs it?G. d'Annunzio University

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: G. d'Annunzio University
Interventions being studied: Drug: Heparin, fondaparinux, vitamin-K antagonists, aspirin

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

cancer patients with a first diagnosis of unsuspected PE

Reasons someone may not be able to joinExclusion criteria

1. age \<18 years; 2. ongoing anticoagulant therapy for previous VTE or indications for long-term anticoagulation other than deep vein thrombosis (DVT) or PE; 3. life expectancy less than 3 months.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

D.C. Veterans Affairs Medical CenterWashington D.C., District of Columbia
Clinical Division of Haematology, Department of Medicine IVienna
Division of Hematology, University of OttawaOttawa
CHU Amiens PicardieAmiens
Arras/Onco Nord Pas de Callais, LoosArras
Hopital Saint AndréBordeaux
Brest HIA Clermont TonnerreBrest
University hospital Centra La Cavale BlancheBrest
Montpellier et clinique du parc a Castelnau le nezCastelnau
Hopital G. Montpied Clermont-FerrandClermont
AP-HP Hopital Louis MourierColombes
Laboratoire d'Hématologie, DijonDijon

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 8, 2019. Always confirm current availability with the study team.

View original record ↗